Our Offering
Biologics
Mammalian
Microbial
ADCs / Bioconjugates
Drug Product
mRNA / LNP
Expression Technologies
Small Molecules
Drug Substance (API)
Particle Engineering
Drug Product
Cell & Gene
Process Development
cGMP manufacturing
Allogeneic
Autologous
Viral Vectors
Bioscience Products
Capsules & Health Ingredients
Pharmaceutical Solutions
Nutraceutical Solutions
Services and Support Solutions
ACHIEV™
Our Company
About Us
Purpose and Strategy
Leadership
History
Locations
Site Tours
Partnering with Us
Events
News and Media
News Releases
Images and Videos
Logo Guidelines
Blog
Podcast
Journalist Inquiries
Investor Relations
Shareholder Information
Agenda and Events
Reporting and Presentations
Consensus and Analysts
Corporate Governance
Ethics and Compliance
Investor Inquiries
Sustainability
Environment
People and Society
Compliance and Integrity
Responsible Sourcing
Global Quality
Sustainability Report
Careers
Overview
Life at Lonza
What We Offer
Career Stories
Job Search
Join Our Talent Community
Recruitment Process
Students, Graduates and Apprentices
Contact
Our Offering
Corporate
Biologics
Mammalian
Microbial
ADCs / Bioconjugates
Drug Product
mRNA / LNP
Expression Technologies
Small Molecules
Drug Substance (API)
Particle Engineering
Drug Product
Cell & Gene
Process Development
cGMP manufacturing
Allogeneic
Autologous
Viral Vectors
Bioscience Products
Capsules & Health Ingredients
Pharmaceutical Solutions
Nutraceutical Solutions
Services and Support Solutions
ACHIEV™
Our Company
Corporate
About Us
Purpose and Strategy
Leadership
History
Locations
Site Tours
Partnering with Us
Events
News and Media
News Releases
Images and Videos
Logo Guidelines
Blog
Podcast
Journalist Inquiries
Investor Relations
Shareholder Information
Agenda and Events
Reporting and Presentations
Consensus and Analysts
Corporate Governance
Ethics and Compliance
Investor Inquiries
Sustainability
Environment
People and Society
Compliance and Integrity
Responsible Sourcing
Global Quality
Sustainability Report
Careers
Corporate
Overview
Life at Lonza
What We Offer
Career Stories
Job Search
Join Our Talent Community
Recruitment Process
Students, Graduates and Apprentices
Contact
Corporate
Home
Knowledge Center
Process development for the production of recombinant antibodies using the glutamine synthetase (GS) system
01 Jan 1992
Process development for the production of recombinant antibodies using the glutamine synthetase (GS) system
You may also be interested in:
Mammalian
Bispecific Antibody
First Name
Last Name
Business Email
Company Name
Country
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas (the)
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia (Plurinational State of)
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory (the)
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cabo Verde
Cambodia
Cameroon
Canada
Cayman Islands (the)
Central African Republic (the)
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands (the)
Colombia
Comoros (the)
Congo (the)
Congo (the Democratic Republic of the)
Cook Islands (the)
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curacao
Cyprus
Czechia
Denmark
Djibouti
Dominica
Dominican Republic (the)
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Eswatini
Ethiopia
Falkland Islands (the) [Malvinas]
Faroe Islands (the)
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories (the)
Gabon
Gambia (the)
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (the)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran (Islamic Republic of)
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea (the Democratic People's Republic of)
Korea (the Republic of)
Kuwait
Kyrgyzstan
Lao People's Democratic Republic (the)
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands (the)
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia (Federated States of)
Moldova (the Republic of)
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands (the)
New Caledonia
New Zealand
Nicaragua
Niger (the)
Nigeria
Niue
Norfolk Island
North Macedonia
Northern Mariana Islands (the)
Norway
Oman
Pakistan
Palau
Palestine, State of
Panama
Papua New Guinea
Paraguay
Peru
Philippines (the)
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russian Federation (the)
Rwanda
Saint Barthelemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan (the)
Suriname
Svalbard and Jan Mayen
Sweden
Switzerland
Syrian Arab Republic (the)
Taiwan (Province of China)
Tajikistan
Tanzania, the United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands (the)
Tuvalu
Uganda
United Kingdom
Ukraine
United Arab Emirates (the)
United States Minor Outlying Islands (the)
United States of America
Uruguay
Uzbekistan
Vanuatu
Venezuela (Bolivarian Republic of)
Viet Nam
Virgin Islands (British)
Virgin Islands (U.S.)
Global
Wallis and Futuna
Western Sahara*
Yemen
Zambia
Zimbabwe
State
Alaska
Alabama
Arkansas
American Samoa
Arizona
California
Colorado
Connecticut
District of Columbia
Delaware
Florida
Georgia
Guam
Hawaii
Iowa
Idaho
Illinois
Indiana
Kansas
Kentucky
Louisiana
Massachusetts
Maryland
Maine
Michigan
Minnesota
Missouri
Northern Mariana Islands
Mississippi
Montana
North Carolina
North Dakota
Nebraska
New Hampshire
New Jersey
New Mexico
Nevada
New York
Ohio
Oklahoma
Oregon
Pennsylvania
Puerto Rico
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
U.S. Minor Outlying Islands (cf. separate entry UM)
Utah
Virginia
Virgin Islands of the U.S.
Vermont
Washington
Wisconsin
West Virginia
Wyoming
Join our community to receive tailored insights and resources. You can unsubscribe at any time.
By clicking "Access Content" you agree to our
Legal Disclaimer
and the
Lonza Privacy and Cookies Policy
.
Loading...
Latest content
Latest briefing from the Knowledge Center
Article
Expert Q&A: Partnering for Success in the Supplement Market
Explore how Lonza's innovative platform and visionary approach to partnership empower brands with a...
Webinar (on-demand)
Innovative AI-Driven Solutions to Address the Growing Complexity of APIs
Developing innovative medicines often involves intricate small-molecule APIs with lengthy synthetic...
Webinar (on-demand)
Charting a Successful CMC Journey for Your ADC Drug Product
Bioconjugates and Antibody drug conjugates (ADCs) are revolutionizing cancer therapy with their...
Interview
Expert Q&A: Accelerate Your ADC Journey
Filling the Need for Integrated Bioconjugate Solutions Antibody drug conjugates (ADCs) are...
Video
mRNA and LNP Encapsulation Capabilities at our Geleen/NL Center of Excellence
Discover how our team, with its impressive mRNA/LNP track record, can help you progress your...
Article
How Emerging Biotechs can Benefit by Partnering with a CDMO for Early Stage Development
The partnership between CDMOs and emerging biotech companies in early-stage development can be...
White paper
Bridging the Gaps in Oral Dosage Research: 4 Focus Areas Highlighted by the UNGAP network
As our designated center of excellence for novel drug delivery systems, Innovaform™ Accelerator is...
Video
CAR-T Cells on the Fast Lane: From T-cell Selection to CAR-T Cell Drug Product in Just 3 Days
In this presentation, we explore the rapid growth of the CAR T market, driven by oncology...
White paper
Unlocking the Potential of Carrier-Based Formulations: A Process Optimization Guide
Carrier-based formulations are commonly used in drug delivery systems, particularly in inhalation...
Webinar (on-demand)
Early Preclinical Development of mRNA/LNP Projects, Transitioning Successfully to cGMP...
View our on-demand webinar exploring the development steps that lead to an mRNA construct optimized...
Webinar (on-demand)
Enhanced GS® CHO Vector Technology for Improved Expression Control of Biotherapeutic Proteins
Many of today’s expression platforms for recombinant protein production have been optimised for the...
Video
Small Molecule API & HPAPI Development Capacity
This video presents Lonza's capabilities, facility locations, and timelines to assist biopharma...
Previous
Next
Cookie Settings